Clinical correlates of <i>JAK2</i>V617F allele burden in essential thrombocythemia
Jaya Kittur(Mayo Clinic), Ayalew Tefferi(Mayo Clinic), Wenting Wu(East China Normal University), Alexandra P. Wolanskyj(Mayo Clinic), Animesh Pardanani(Mayo Clinic), Christy M. Finke(Mayo Clinic), Rhett P. Ketterling(Mayo Clinic in Arizona), Ryan A. Knudson(Mayo Clinic), Naseema Gangat(Mayo Clinic in Arizona), Chin‐Yang Li(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 154
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907